Clinical trial · Interventional
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
A Randomized, Open-Label, Four-Cohort, Parallel Design Study to Evaluate the Effect of Itraconazole or Rifampin on the Single-Dose Pharmacokinetics of BMS-986205 in Normal Healthy Participants
NCT03346837CI-TRIAL-00031855completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignancies Multiple | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986205 | Drug | — | UNRESOLVED |
| Itraconazole | Drug | — | UNRESOLVED |
| Rifampin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Inhibition (Cohort 1)
- description
- Single oral dose BMS-986205
- interventionNames
- Drug: BMS-986205
- type
- EXPERIMENTAL
- label
- Inhibition (Cohort 2)
- description
- Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4
- interventionNames
- Drug: BMS-986205
- Drug: Itraconazole
- type
- EXPERIMENTAL
- label
- Induction (Cohort 3)
- description
- Single oral dose BMS-986205
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Body mass index 18.0 to 32.0 kg/m2, inclusive * Must have normal renal function demonstrated by GFR, calculated by Chronic Kidney Disease Epidemiology Collaboration formula * Women must not be of childbearing potential (cannot become pregnant) Exclusion Criteria: * Any significant acute or chronic medical illness * History of glucose-6-phosphodiesterase (G6PD) deficiency * Personal or family history of cytochrome b5 reductase deficiency Other protocol defined inclusion / exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.